MaaT Pharma S.A. (MAAT.PA) Stock Analysis & Winston Score

MaaT Pharma is a French biotechnology company that works on treatments using the human gut microbiome — the trillions of bacteria living in the digestive system. The company develops therapies that restore a healthy balance of gut bacteria in patients who have had their microbiome severely disrupted, mainly by chemotherapy or bone marrow transplants. Its main focus is on blood cancer patients undergoing stem cell transplants, where gut health can directly affect survival. MaaT Pharma earns revenue through research partnerships and grants, as it has no approved product on the market yet. The company is based in Lyon, France, and operates primarily in Europe, with a very small market cap reflecting its early-stage status. Its pipeline centers on MaaT013, a microbiome restoration therapy in clinical trials, and the key risk is straightforward: if clinical trials fail to show strong enough results, the company may struggle to raise the funding it needs to survive.